We observed that many cancer-related and immune-related pathways or hallmarks were enriched in high-risk groups, such as epithelial-mesenchymal transition, angiogenesis, allograft rejection, antigen prepossessing and presenting and intestinal immune network for IgA production. The gene discussed is CD79A; the disease is cancer.